drugset
drugset / Trial / NCT03779230

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse

NCT03779230 ↗

Phase 1/2 Completed 20 enrolled Philogen S.p.A.
NaSingle-groupOpen-labelTreatment

Summary

Open label, non-randomized, mono-center Phase I/II study in subjects with IDH-wildtype WHO grade III / IV glioma at first relapse.

Timeline

Start
2019-05-31
Primary completion
2023-06-27
Completion
2023-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Onfekafusp alfa Protein / enzyme biologic 10 ug/kg —
Subject Onfekafusp alfa Protein / enzyme biologic 13 ug/kg —

Indications

brain glioma